{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:20:07Z","timestamp":1791904807866,"version":"4.3.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1097\/ftd.0b013e31803bb54e","type":"journal-article","created":{"date-parts":[[2007,4,6]],"date-time":"2007-04-06T08:04:49Z","timestamp":1175846689000},"page":"171-176","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of Low-Dose Boosted Saquinavir Once Daily Plus Nucleoside Reverse Transcriptase Inhibitors in Pregnant HIV-1-Infected Women With a Therapeutic Drug Monitoring Strategy"],"prefix":"10.1097","volume":"29","author":[{"given":"Luis F","family":"Lopez-Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Ruiz-Valderas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Marquez-Solero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milagros","family":"Garc\u00eda-Lazaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pompeyo","family":"Viciana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Rodriguez-Ba\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ocampo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210129","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJM199908053410601","article-title":"Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine.","volume":"341","author":"Mofenson","year":"1999","journal-title":"N Engl J Med"},{"key":"R2-4-20210129","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/00002030-199907300-00016","article-title":"Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one.","volume":"13","year":"1999","journal-title":"AIDS"},{"key":"R3-4-20210129","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/00042560-200204150-00009","article-title":"Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission.","volume":"29","author":"Cooper","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R5-4-20210129","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00003495-200060020-00016","article-title":"Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.","volume":"60","author":"Figgitt","year":"2000","journal-title":"Drugs"},{"key":"R6-4-20210129","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00042560-200208010-00006","article-title":"Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission.","volume":"30","author":"Vithayasai","year":"2002","journal-title":"J Acquir Immune Defic"},{"key":"R7-4-20210129","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1310\/PUY3-5JWL-FX2B-98VU","article-title":"Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women.","volume":"2","author":"Acosta","year":"2001","journal-title":"HIV Clin Trials"},{"key":"R8-4-20210129","doi-asserted-by":"crossref","first-page":"F29","DOI":"10.1097\/00002030-199704000-00001","article-title":"Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients.","volume":"11","author":"Merry","year":"1997","journal-title":"AIDS"},{"key":"R9-4-20210129","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2165\/00003495-200363120-00007","article-title":"Saquinavir: a review of its use in boosted regimens for treating HIV infection.","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"key":"R10-4-20210129","first-page":"101","article-title":"Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.","volume":"4","author":"Kurowski","year":"1999","journal-title":"Eur J Med Res"},{"key":"R11-4-20210129","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1128\/AAC.44.10.2672-2678.2000","article-title":"Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.","volume":"44","author":"Kilby","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-4-20210129","doi-asserted-by":"crossref","first-page":"F103","DOI":"10.1097\/00002030-200006160-00003","article-title":"Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.","volume":"14","author":"Van HeeswijK RPG, V Veldkamp","year":"2000","journal-title":"AIDS"},{"key":"R13-4-20210129","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/00042560-200204150-00006","article-title":"Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules\/ritonavir (1600\/100 mg): HIVNAT 001.3 study.","volume":"29","author":"Cardiello","year":"2002","journal-title":"J Acquir Immune Defic"},{"key":"R14-4-20210129","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00126334-200302010-00019","article-title":"Once-daily saquinavir-sgc plus low-dose Ritonavir (1200\/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy.","volume":"32","author":"Lopez-Cortes","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R15-4-20210129","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/135965350400900202","article-title":"Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).","volume":"9","author":"Lamotte","year":"2004","journal-title":"Antivir Ther"},{"key":"R16-4-20210129","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/135965350501000604","article-title":"A prospective study of efficacy and safety of once-daily saquinavir\/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.","volume":"10","author":"Ananworanich","year":"2005","journal-title":"Antivir Ther"},{"key":"R17-4-20210129","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1468-1293.2005.00274.x","article-title":"The 48 week efficacy of once-daily saquinavir\/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.","volume":"6","author":"Cardiello","year":"2005","journal-title":"HIV Med"},{"key":"R18-4-20210129","first-page":"523","article-title":"Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 Study.","volume":"39","author":"Ananworanich","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-4-20210129","first-page":"36","article-title":"Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule\/ritonavir in antiretroviral-naive, HIV-infected patients.","volume":"8","author":"Montaner","year":"2006","journal-title":"Med Gen Med"},{"key":"R22-4-20210129","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1128\/AAC.48.2.430-436.2004","article-title":"Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women.","volume":"48","author":"Acosta","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"R23-4-20210129","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1086\/313852","article-title":"Pharmacodynamics of HIV-1 protease inhibitors.","volume":"30","author":"Acosta","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"R24-4-20210129","first-page":"1","article-title":"Flexner CW, Piscitelli SC, ed.","volume":"16","year":"2002","journal-title":"AIDS"},{"key":"R25-4-20210129","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2165\/00003088-200443150-00002","article-title":"Pharmacokinetics of antiretrovirals in pregnant women.","volume":"43","author":"Mirochnick","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R27-4-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1310\/RWR8-2E61-YYFD-TWMV","article-title":"Once-daily saquinavir-hgc plus low dose ritonavir (1200\/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy.","volume":"4","author":"Lopez-Cortes","year":"2003","journal-title":"HIV Clin Trials"},{"key":"R28-4-20210129","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.283.18.2417","article-title":"Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.","volume":"283","author":"Hirsch","year":"2000","journal-title":"JAMA"},{"key":"R29-4-20210129","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00042560-199810010-00015","article-title":"Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. NV15107 Study Group.","volume":"19","author":"Lalezari","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"R30-4-20210129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00003088-199937010-00005","article-title":"Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients.","volume":"37","author":"Gieschke","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"R32-4-20210129","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1128\/AAC.48.12.4687-4692.2004","article-title":"Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.","volume":"48","author":"Marcelin","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R33-4-20210129","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1097\/00002030-200209270-00016","article-title":"Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir\/ritonavir.","volume":"16","author":"Valer","year":"2002","journal-title":"AIDS"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31803bb54e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T02:31:23Z","timestamp":1707791483000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-200704000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31803bb54e","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}